Anti human papillomavirus vaccine: The checkmate to human papillomavirus?

Cervical cancer is the second most frequently found neoplasia in women worldwide. At least 95% of cervical cancers contain viral DNA which, in 80% of cases, belongs to one of the human papillomavirus (HPV) viral types at high oncogenic risk: 16, 18, 31 and 45. HPV is, at this point, considered the first "necessary cause" of cervical cancer, against which primary prevention with a reduction in the risk of infection can be carried out. Numerous molecular biological studies have been conducted to identify the biological markers of this infection and to refine an effective and well tolerated vaccine capable of preventing HPV infection as well as possibly treating those cases in which the infection has already caused an HPV-related disease of the genital tract. In the near future, the real primary prevention of this disease will be conducted, similar to what occurred for Hepatitis B, using immunoprophylaxis with an anti-cancer vaccine.

Human papillomavirus; Vaccine; Clinical trial

[1] Casone A.: "Vaccini e vaccinazioni antinfettive. Accademia Nazionale Medica". Forum Service Editore s.c.a.r.l., 2001.

[2] Zur Hausen H.: "Viruses in human cancer". Science, 1991, 254, 1167.

[3] Brown D.R., Schroeder J.M., Bryan J.T., Stoler M.H., Fife K.H.: "Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients". J. Clin. Microb., 1999, 37, 3316.

[4] WHO: "The current status of development of prophylactic vaccine against human papillomavirus infection". Report of a techmcal meeting, Geneva, 16-18 February 1999. Department of Vaccines and Other Biologicals. World Health Organization

[5] Bosch F.X., Lorincz A., Munoz N., Meijer C.J.L.M., Shah K.V.:'The causal relation between human papillomavirus and cervical cancer". J. Clin. Pathol., 2002, 55, 244.

[6] Stanley M.A., Masterson P.J., Nicholls P.K.: "In vitro and animal models for antiviral therapy for papillomavirus infections". Antiv. Chem. Chemo., 1997, 8, 381.

[7] Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J. et al.: "Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 LI virus-like particle vaccine". J. Natl. Cancer Inst., 2001, 3, 284.

[8] Schiller J.T., Lowy D.R.: "Papillomavirus-like particle based vaccines: cervical cancer and beyond". Expert. Opin. Biol. Ther., 2001, 4, 571.

[9] Evans T.G., Bonnez W., Rose R.C., Rose R.C., Koeig S., Demeter L. et al.: "A phase 1 study of a recombinant virus-like particle vaccine against human papillomavirus type 11 in healthy adult volunteers". J. Infect. Dis., 2001, 183, 1485.

[10] Zhang L.F., Zhou J., Chen S., Cai L.L., Bao Q.Y., Zheng F.Y. et al.: "HPV6b virus like particles are potent immunogens without adjuvant in men". Vaccine, 2000, 18, 1051.

[11] Emeny R.T., Wheeler C.M., Jansen K.U., Hunt W.C., Fu T.M., Smith J.F. et al.: "Priming of human papillomavirus type 11-specific humoral and cellular response in college aged women with a virus-like particle vaccine". J. Viral., 2002, 76, 7832.

[12] Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B. et al.: "A controlled trial of a human papillomav,rus type 16 vaccine". N. Engl. J. Med., 2002, 347, 1645.

[13] Muller M., Zhou J., Reed T.D., Rittmuller C., Burger A., Gabelsberger J. et al.: "Chimeric papillomavirus-like particles". Viral., 1997, 234, 93.

[14] Peng S., Frazer I.H., Fernando G.J., Zhou J.: "Papillomavirus-like particles can deliver defined CT L epitopes to the MHC class I pathway". Viral., 1998, 240, 147.

[15] Borysiewicz L., Fiander A., Nimako M., Man S., Wilkinson G.W., Westmoreland D. et al.: "A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer". Lancet, 1996, 347, 1523.

[16] Adams M., Borysiewicz L., Fiander A., Man S., Jasani B., Navabi H. et al.: "Clinical studies of human papillomavirus vaccines in pre-invasive and invasive cancer". Vaccine, 2001, 19, 2549.

[17] Van Driel W.J., Ressing M.E., Kenter G.G., Brandt R.M.P., Krul E.J.T., van Rossum A.B. et al.: "Vaccination with HPV 16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial". Eur. J. Cancer, 1999, 35, 946.

[18] Khleif S.N., Berzofsky J., Berastein S., Contoise D., Woitowicz M.: "A phase Il HPV 16 E6 and E7 peptides vaccination in patients with advanced cervical cancer". l 8'h International Papillomavirus Conference, Barcelona, Spain. Program and Abstract book (abstr. 380).

[19] Muderspach L., Wilczynski S., Roman L., Bade L., Felix J., Small L.A. et al.: "A phase I trial of a human papillomavirus (HPV ) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive". Clin. Cancer Res., 2000, 6, 3406.

[20] Da Silva D., Eiben G.L., Fausch S.C., Wakabayashi M.T., Rudolf M.P., Velders M.P., Dast W.M.: "Cervical cancer vaccines: emerging concepts and developments". J. Cell. Physiol., 2001, 186, 169.

[21] Stanley M.A.: "Immunobiology of Papillomavirus infections". J. Reprod. Immunol., 2001, 52, 45.

[22] Bamelli C., Roden R.B., Potts A., Schiller J., De Grandi P., Nardeli-Haefliger D.: "Nasal immunization of mice with human papillomavirus type 16 V LP elicits neutralizing antibodies in mucosal secretions". J. Viral., 1998, 72, 8220.

[23] Nardeli-Haefliger D., Roden R.B., Benyacoub J., Sahli R., Kraehenbuhl J.P., Schiller J.T. et al.: "Human papillomavirus type 16 VLP expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice". Infect Immunol., 1997, 65, 3328.

[24] Duggan-Keen M.F., Brown M.D., Satcey S.N., Stern P.L.: "Papillomavirus vaccines". Front. Biosc., 1998, 3, 1192.

[25] Schiller J.T.: "Pap仆lomavirus-like particle vaccines for cervical cancer". Mal. Med. Today, 1999, 5, 209.